2026
May
Intratumoral anti-CTLA-4 could reduce severe AEs: Results from a phase 1b clinical trial
May 13, 2026
The combination of nivolumab (anti-PD-1) and ipilimumab (anti-CTLA-4), both administered intravenously, has been approved for the treatment of cancer in a variety of settings since 2015, but its use is frequently hindered by severe adverse events, more often associated with the use of anti-CTLA-4. In an effort to reduce this toxicity, Tselikas and...
NK cells unleashed by Treg ablation
May 6, 2026
When tumors lose expression of MHC-I under the selective pressure of CD8+ T cells, NK cells may step in and take on a more prominent antitumor role, but often this is still insufficient to control tumors. Investigating potential mechanisms limiting NK cell antitumor activity, Zhang et al. found that Tregs have a strong...
